Literature DB >> 31160470

Wake Up and Smell the Fusions: Single-Modality Molecular Testing Misses Drivers.

Kurtis D Davies1, Dara L Aisner2.   

Abstract

Multitarget assays have become common in clinical molecular diagnostic laboratories. However, all assays, no matter how well designed, have inherent gaps due to technical and biological limitations. In some clinical cases, testing by multiple methodologies is needed to address these gaps and ensure the most accurate molecular diagnoses.See related article by Benayed et al., p. 4712. ©2019 American Association for Cancer Research.

Mesh:

Year:  2019        PMID: 31160470     DOI: 10.1158/1078-0432.CCR-19-1361

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  4 in total

1.  Kinase fusion-related thyroid carcinomas: distinct pathologic entities with evolving diagnostic implications.

Authors:  Ying-Hsia Chu; Peter M Sadow
Journal:  Diagn Histopathol (Oxf)       Date:  2021-03-31

2.  Lung Cancer Biomarker Speak: Teach Me the Language.

Authors:  Beth Sandy; Jennifer Morrissette
Journal:  J Adv Pract Oncol       Date:  2022-05-23

3.  Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.

Authors:  Peiyi Xia; Lan Zhang; Pan Li; Enjie Liu; Wencai Li; Jianying Zhang; Hui Li; Xiaoxing Su; Guozhong Jiang
Journal:  J Transl Med       Date:  2021-07-16       Impact factor: 5.531

Review 4.  Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach.

Authors:  May T Cho; Sepideh Gholami; Dorina Gui; Sooraj L Tejaswi; Ghaneh Fananapazir; Nadine Abi-Jaoudeh; Zeljka Jutric; Jason B Samarasena; Xiaodong Li; Jennifer B Valerin; Jacob Mercer; Farshid Dayyani
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.